Pharma Pulse

Pharma news, minus the noise.

High-density pharmaceutical news intelligence for health and pharma professionals. We synthesize global pharma discourse into a 10-minute technical briefing delivered by 0700 ET.

AI Pharma Pulse

AI Pharma Pulse: Ipsen’s $1.7B Kartos Grab, Dexcom’s OTC CGM, and a Sobi Gout Setback — June 30, 2026

[ ARCHIVE ]
Regulatory
FDA approves first drug for hepatitis delta virus

Historic first-in-class approval for bulevirtide; HDV affects ~15M patients co-infected with HBV globally.

Funding
NewLimit raises $435M to advance epigenetic reprogramming

Series B led by a16z Biohealth. Funds IND-enabling work for partial reprogramming candidates targeting age-related decline.

Read Full Briefing
Efficiency

AI-Curated Density

LLMs scan multiple sources to surface technical signals.

Precision

10-Minute Read

Information architecture optimized for rapid scanning. Bulleted updates with source links for deep dives.

Access

Open Intelligence

Zero cost, zero friction. We believe pharma industry transparency is a public utility for healthcare professionals.

ARCHIVE
2026-06-30AI Pharma Pulse: Ipsen’s $1.7B Kartos Grab, Dexcom’s OTC CGM, and a Sobi Gout Setback — June 30, 20262026-06-29AI Pharma Pulse: FDA Clears Hepcludex, Otsuka’s ADHD Win, and AstraZeneca Bone Data — June 29, 20262026-06-28AI Pharma Pulse: FDA Approves First HDV Therapy, Hepcludex, Opening $200M Market — June 28, 20262026-06-27AI Pharma Pulse: Biogen cuts Apellis, HDV drug approved, and Tzield gains pediatric label — June 27, 20262026-06-26AI Pharma Pulse: FDA Clears First‑Line TNBC Boost, HDV Breakthrough, and Otsuka ADHD Win — June 26, 20262026-06-25AI Pharma Pulse: FDA greenlights sacituzumab, Otsuka ADHD win, and Boehringer AI deal — June 25, 20262026-06-21AI Pharma Pulse: Biogen’s $1B RayThera Grab, Moderna’s Flu Vote, Novocure’s Device Failure — June 21, 20262026-06-15AI Pharma Pulse: Lilly’s $2.3B Ajax Bet, HDV’s First Therapy, and Capivasertib Oncology Approval — June 15, 20262026-06-14AI Pharma Pulse: Lilly’s $2.3B JAK Bet, Novartis’ $12B Avidity Win, and First HDV Approval — June 14, 20262026-06-13AI Pharma Pulse: FDA Approves HDV Therapy, AstraZeneca Launches GLP‑1 Pill, and Sanofi’s Immune Drug Fails — June 13, 20262026-06-12AI Pharma Pulse: Novartis $12B Avidity Deal Tops Headlines, HDV Approval, Takeda TYK2 Win — June 12, 20262026-06-11AI Pharma Pulse: FDA Greenlights First‐in‑Class HDV Therapy as Takeda Scores Psoriasis Win — June 11, 20262026-06-10AI Pharma Pulse: GSK’s $10.6B Nuvalent Buyout, FDA’s First HDV Drug, Sanofi’s Autoimmune Halt — June 10, 20262026-06-09AI Pharma Pulse: GSK’s $10.6B Nuvalent Buyout, FDA’s First HDV Approval, J&J’s Firefly Deal, and Tango Pancreatic Data — June 9, 20262026-06-07AI Pharma Pulse: FDA Greenlights First HDV Therapy, Innovent’s ADC Wins Phase 3, and Alnylam Splurges on AI — June 7, 20262026-06-06AI Pharma Pulse: FDA Clears First HDV Therapy, Innovent Scores ADC Win, and Pfizer’s Obesity Bet Gets a Boost — June 6, 20262026-06-03AI Pharma Pulse: Lilly‑Ascidian $1.9B RNA Deal, FDA Approves First HDV Therapy, and House Bill Targets China Biotech Deals — June 3, 2026

Join countless others

The pharma briefing for people who want to stay sharp without the noise.